Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Acquisition of Caliper Clears Anti-Trust Review

NEW YORK (GenomeWeb News) – PerkinElmer today said that its planned acquisition of Caliper Life Sciences has cleared anti-trust reviews in the US and Germany.

The $600 million deal, which was signed early last month, still requires the approval of Caliper's stockholders, among other remaining conditions. The firms previously said that they expect the transaction to close in the fourth quarter of this year, but they didn't provide an update to that expectation today.

The deal will broaden PerkinElmer's reach in the life sciences research space, providing the firm with Caliper's portfolio of imaging, microfluidics, automation, and sample preparation platforms and technologies. It also will combine Caliper's imaging instrumentation for in vivo imaging applications with PerkinElmer's broad offering of imaging reagents and set up the combined firm with further growth opportunities in molecular diagnostics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.